PARTHENOLIDE: SUGGESTED DRUG FOR COVID-19

被引：0
|
作者：
Nemati, M. [1 ]
Pouya, F. Danesh [1 ]
Asl, E. Roshni [1 ]
Rasmi, Y. [1 ,2 ]
机构：
[1] Urmia Univ Med Sci, Dept Biochem, Sch Med, Orumiyeh, Iran
[2] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran
来源：
INFEKTSIYA I IMMUNITET | 2020年 / 10卷 / 04期
关键词：
Parthenolide; COVID-19; NF-kappa B; ACTIVATION; INHIBITORS;
D O I：
10.15789/2220-7619-PSD-1509
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1 beta (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.
引用
收藏
页码：789 / 791
页数：3
相关论文
共 50 条
  • [1] Cytokine storm in COVID-19 and parthenolide: Preclinical evidence
    Bahrami, Mohsen
    Kamalinejad, Mohammad
    Latifi, Seied Amirhossein
    Seif, Farhad
    Dadmehr, Majid
    PHYTOTHERAPY RESEARCH, 2020, 34 (10) : 2429 - 2430
  • [2] Pentoxifylline: An Immunomodulatory Drug for the Treatment of COVID-19
    Dhameliya, Hiren A.
    Thakkar, Vasudev R.
    Trivedi, Gauravi N.
    Mesara, Sureshkumar N.
    Subramanian, R. B.
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2020, 14 : 861 - 867
  • [3] DNR and COVID-19: The Ethical Dilemma and Suggested Solutions
    Sultan, Hala
    Mansour, Razan
    Shamieh, Omar
    Al-Tabba, Amal
    Al-Hussaini, Maysa
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [4] Diverse Manifestations of COVID-19: Some Suggested Mechanisms
    Zaman, Md S.
    Sizemore, Robert C.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (18)
  • [5] Diacerein: A potential multi-target therapeutic drug for COVID-19
    de Oliveira, Pedro Goncalves
    Termini, Lara
    Durigon, Edison Luiz
    Lepique, Ana Paula
    Sposito, Andrei C.
    Boccardo, Enrique
    MEDICAL HYPOTHESES, 2020, 144
  • [6] COVID-19 Drug Development
    Kim, Seungtaek
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 32 (01) : 1 - 5
  • [7] COVID-19 Drug Interactions
    Surmelioglu, Nursel
    Demirkan, Kutay
    JOURNAL OF CRITICAL & INTENSIVE CARE, 2020, 11 : 43 - 45
  • [8] Drug repositioning for COVID-19
    Benavides-Cordoba, Vicente
    COLOMBIA MEDICA, 2020, 51 (02):
  • [9] Overview of therapeutic drug research for COVID-19 in China
    Li, Heng
    Yang, Li
    Liu, Fei-fei
    Ma, Xin-na
    He, Pei-lan
    Tang, Wei
    Tong, Xian-kun
    Zuo, Jian-ping
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (09) : 1133 - 1140
  • [10] Antiviral Drug Discovery for the Treatment of COVID-19 Infections
    Ng, Teresa, I
    Correia, Ivan
    Seagal, Jane
    DeGoey, David A.
    Schrimpf, Michael R.
    Hardee, David J.
    Noey, Elizabeth L.
    Kati, Warren M.
    VIRUSES-BASEL, 2022, 14 (05):
12345